Cellares Secures 10-Year Deal with Cabaletta Bio for Autoimmune CAR T Therapy
Event summary
- Cellares and Cabaletta Bio signed a 10-year commercial supply agreement for the automated manufacture of rese-cel, an investigational CAR T cell therapy for autoimmune diseases.
- The deal secures long-term manufacturing capacity to address global patient demand, following the first patient dosing milestone with rese-cel manufactured on Cellares' automated platform.
- Cellares' Cell Shuttle and Cell Q platforms aim to deliver up to 10× higher throughput than conventional CDMO approaches with comparable footprint and headcount.
The big picture
The agreement underscores a strategic shift toward automated, scalable manufacturing solutions for cell therapies, particularly in autoimmune diseases where patient populations are significantly larger than in oncology. This deal positions Cellares as a key player in enabling cost-efficient, high-throughput production of next-generation therapies.
What we're watching
- Execution Risk
- Whether Cellares can sustain the promised 10× higher throughput and maintain consistent quality over the 10-year agreement.
- Market Expansion
- The pace at which Cabaletta Bio scales rese-cel production to meet global demand for autoimmune therapies.
- Regulatory Dynamics
- How FDA and other regulatory bodies respond to the automated manufacturing model as it becomes more prevalent in cell therapy production.
Related topics